The prostate cancer biomarkers PSA (also known as KLK3), PSMA, and PSCA were evaluated in six [50,78,79,82,87,88], four [50,130,131,132], and two [82,87] papers, respectively. This evidence concerns the gene FOLH1 and prostate carcinoma.